SG11202104248UA - Monoclonal antibody that specifically binds to cd20 - Google Patents
Monoclonal antibody that specifically binds to cd20Info
- Publication number
- SG11202104248UA SG11202104248UA SG11202104248UA SG11202104248UA SG11202104248UA SG 11202104248U A SG11202104248U A SG 11202104248UA SG 11202104248U A SG11202104248U A SG 11202104248UA SG 11202104248U A SG11202104248U A SG 11202104248UA SG 11202104248U A SG11202104248U A SG 11202104248UA
- Authority
- SG
- Singapore
- Prior art keywords
- monoclonal antibody
- specifically binds
- binds
- specifically
- monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018138510A RU2724469C2 (en) | 2018-10-31 | 2018-10-31 | Monoclonal antibody which specifically binds to cd20 |
| PCT/RU2019/050205 WO2020091634A1 (en) | 2018-10-31 | 2019-10-30 | Monoclonal antibody that specifically binds to cd20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104248UA true SG11202104248UA (en) | 2021-05-28 |
Family
ID=70462324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104248UA SG11202104248UA (en) | 2018-10-31 | 2019-10-30 | Monoclonal antibody that specifically binds to cd20 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220089761A1 (en) |
| EP (1) | EP3875486A4 (en) |
| JP (1) | JP2022506430A (en) |
| KR (1) | KR20210084604A (en) |
| CN (1) | CN113272329A (en) |
| AR (1) | AR116937A1 (en) |
| AU (1) | AU2019373999A1 (en) |
| BR (1) | BR112021008326A2 (en) |
| CA (1) | CA3117486A1 (en) |
| CL (1) | CL2021001104A1 (en) |
| CO (1) | CO2021005178A2 (en) |
| EA (1) | EA202191173A1 (en) |
| EC (1) | ECSP21028958A (en) |
| IL (1) | IL282742A (en) |
| JO (1) | JOP20210100A1 (en) |
| MA (1) | MA53186B2 (en) |
| MX (1) | MX2021005033A (en) |
| PE (1) | PE20211731A1 (en) |
| PH (1) | PH12021550991A1 (en) |
| RU (1) | RU2724469C2 (en) |
| SG (1) | SG11202104248UA (en) |
| TW (1) | TW202031682A (en) |
| UY (1) | UY38432A (en) |
| WO (1) | WO2020091634A1 (en) |
| ZA (1) | ZA202102874B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024025440A1 (en) * | 2022-07-26 | 2024-02-01 | Joint Stock Company "Biocad" | Pharmaceutical composition of anti-cd20 antibody and use thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
| US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| FI891226A (en) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | RESEPTORDETERMINANTER I ANTI-T-CELLER FOER BEHANDLING AV AUTOIMMUNSJUKDOM. |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
| RO110397B1 (en) | 1989-03-21 | 1996-01-30 | Immune Response Corp San Diego | Vaccine for the prevention or treatment of some illnesses which result from pathogen answers, through specific t-cells populations, preparation process and diagnosis methods and treatment with this thereof |
| ATE161850T1 (en) | 1989-07-19 | 1998-01-15 | Connetics Corp | T-CELL RECEPTOR PEPTIDES AS A CURE FOR AUTOIMMUNE AND MALIGNANT DISEASES |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (en) | 1990-08-29 | 1997-09-15 | Genpharm Int | PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| DE69333807T2 (en) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR |
| WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE19544393A1 (en) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistic herbicidal mixtures |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| AU2003208415B2 (en) * | 2002-02-14 | 2009-05-28 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| AU2011226858B2 (en) * | 2002-12-16 | 2015-01-22 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| AR042485A1 (en) | 2002-12-16 | 2005-06-22 | Genentech Inc | HUMANIZED ANTIBODY THAT JOINS THE HUMAN CD20 |
| UA99933C2 (en) | 2003-04-09 | 2012-10-25 | Дженентек, Инк. | Therapy of autoimmune disease in a patient with an inadequate response to tnf-alpha inhibitor |
| DOP2006000029A (en) * | 2005-02-07 | 2006-08-15 | Genentech Inc | ANTIBODY VARIANTS AND USES THEREOF. (VARIATIONS OF AN ANTIBODY AND USES OF THE SAME) |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| RU2489166C2 (en) | 2006-04-09 | 2013-08-10 | Джинентех, Инк. | Using antibodies for treating autoimmune diseases in patient with inadequate response to tnf-alpha inhibitor |
| WO2011100398A1 (en) * | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Cd20 antibodies and uses thereof |
| CN102190728B (en) * | 2010-03-17 | 2014-07-02 | 永卓博济(上海)生物医药技术有限公司 | Novel humanized anti-CD20 monoclonal antibody |
-
2018
- 2018-10-31 RU RU2018138510A patent/RU2724469C2/en active
-
2019
- 2019-10-29 TW TW108139053A patent/TW202031682A/en unknown
- 2019-10-30 KR KR1020217016587A patent/KR20210084604A/en active Search and Examination
- 2019-10-30 BR BR112021008326-0A patent/BR112021008326A2/en unknown
- 2019-10-30 UY UY0001038432A patent/UY38432A/en unknown
- 2019-10-30 AU AU2019373999A patent/AU2019373999A1/en active Pending
- 2019-10-30 US US17/288,234 patent/US20220089761A1/en active Pending
- 2019-10-30 CA CA3117486A patent/CA3117486A1/en active Pending
- 2019-10-30 SG SG11202104248UA patent/SG11202104248UA/en unknown
- 2019-10-30 MX MX2021005033A patent/MX2021005033A/en unknown
- 2019-10-30 WO PCT/RU2019/050205 patent/WO2020091634A1/en unknown
- 2019-10-30 CN CN201980087511.2A patent/CN113272329A/en active Pending
- 2019-10-30 JO JOP/2021/0100A patent/JOP20210100A1/en unknown
- 2019-10-30 JP JP2021523796A patent/JP2022506430A/en active Pending
- 2019-10-30 EA EA202191173A patent/EA202191173A1/en unknown
- 2019-10-30 EP EP19880700.0A patent/EP3875486A4/en active Pending
- 2019-10-30 PE PE2021000556A patent/PE20211731A1/en unknown
- 2019-10-30 MA MA53186A patent/MA53186B2/en unknown
- 2019-10-31 AR ARP190103167A patent/AR116937A1/en unknown
-
2021
- 2021-04-22 CO CONC2021/0005178A patent/CO2021005178A2/en unknown
- 2021-04-22 EC ECSENADI202128958A patent/ECSP21028958A/en unknown
- 2021-04-28 IL IL282742A patent/IL282742A/en unknown
- 2021-04-28 CL CL2021001104A patent/CL2021001104A1/en unknown
- 2021-04-29 ZA ZA2021/02874A patent/ZA202102874B/en unknown
- 2021-04-30 PH PH12021550991A patent/PH12021550991A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3117486A1 (en) | 2020-05-07 |
| RU2724469C2 (en) | 2020-06-23 |
| EP3875486A1 (en) | 2021-09-08 |
| BR112021008326A2 (en) | 2021-08-31 |
| AR116937A1 (en) | 2021-06-30 |
| US20220089761A1 (en) | 2022-03-24 |
| RU2018138510A (en) | 2020-04-30 |
| CN113272329A (en) | 2021-08-17 |
| KR20210084604A (en) | 2021-07-07 |
| MA53186A1 (en) | 2022-02-28 |
| WO2020091634A1 (en) | 2020-05-07 |
| JP2022506430A (en) | 2022-01-17 |
| TW202031682A (en) | 2020-09-01 |
| CO2021005178A2 (en) | 2021-04-30 |
| PH12021550991A1 (en) | 2021-10-04 |
| MX2021005033A (en) | 2021-06-15 |
| MA53186B2 (en) | 2023-05-31 |
| AU2019373999A1 (en) | 2021-05-27 |
| CL2021001104A1 (en) | 2021-12-03 |
| PE20211731A1 (en) | 2021-09-06 |
| EP3875486A4 (en) | 2022-08-03 |
| IL282742A (en) | 2021-06-30 |
| ZA202102874B (en) | 2022-06-29 |
| ECSP21028958A (en) | 2021-05-31 |
| EA202191173A1 (en) | 2021-07-28 |
| RU2018138510A3 (en) | 2020-04-30 |
| UY38432A (en) | 2020-05-29 |
| JOP20210100A1 (en) | 2023-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258057A1 (en) | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies | |
| ZA201804077B (en) | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof | |
| IL283812B (en) | Humanized anti-human-pd-1 antibody | |
| IL263936A (en) | Humanized monoclonal antibodies that target ve-ptp (hptp-beta) | |
| DK3441086T3 (en) | Monoclonal anti-PD-1 antibody | |
| ZA201907065B (en) | Monoclonal antibody to pd-l1 | |
| ZA202109374B (en) | Monoclonal antibody that binds specifically to gitr | |
| EP3705134A4 (en) | Pharmaceutical composition containing anti-pd-l1 humanized monoclonal antibody | |
| IL282756A (en) | Humanized anti-sirpα antibodies | |
| ZA202004908B (en) | Bispecific antibody | |
| IL277588A (en) | Monoclonal antibodies that bind to ssea4 and uses thereof | |
| EP3825334A4 (en) | Anti-her3 humanized monoclonal antibody | |
| EP3325511A4 (en) | Humanized monoclonal antibody specific to syndecan-1 | |
| ZA202104356B (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| ZA202205226B (en) | Ri-labeled humanized antibody | |
| EP3677677A4 (en) | Anti-hsv gb monoclonal antibody or antigen-binding fragment thereof | |
| ZA202102874B (en) | Monoclonal antibody that specifically binds to cd20 | |
| EP4034568A4 (en) | Novel anti-pd-l1 antibodies | |
| GB201911211D0 (en) | Monoclonal antibodies against ambra-1 | |
| SG11202012133TA (en) | Variant antibody that binds cd38 | |
| GB201910138D0 (en) | Anti-pd-l1 antibodies | |
| EP3471762A4 (en) | Humanized and chimeric monoclonal antibodies to cd81 | |
| ZA202002044B (en) | Monoclonal antibody to il-5rα | |
| GB201820006D0 (en) | Humanised anti-IL17BR antibody | |
| SG11202102765RA (en) | Humanised anti-n-truncated amyloid beta monoclonal antibody |